Michael B Atkins

Michael B Atkins

UNVERIFIED PROFILE

Are you Michael B Atkins?   Register this Author

Register author
Michael B Atkins

Michael B Atkins

Publications by authors named "Michael B Atkins"

Are you Michael B Atkins?   Register this Author

100Publications

3089Reads

11Profile Views

A case of checkpoint inhibitor-induced celiac disease.

J Immunother Cancer 2019 Aug 5;7(1):203. Epub 2019 Aug 5.

Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, 3800 Reservoir Road, NW, Washington, DC, 20007, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0694-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683380PMC
August 2019

Genetic Associations with Indoor Tanning Addiction among non-Hispanic White Young Adult Women.

Ann Behav Med 2019 Jun 11. Epub 2019 Jun 11.

Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/abm/kaz021DOI Listing
June 2019

Management of metastatic cutaneous melanoma: updates in clinical practice.

Ther Adv Med Oncol 2019 22;11:1758835919851663. Epub 2019 May 22.

Department of Medical Oncology, Hospital Israelita Albert Einstein, São Paulo, SP, Brazila and Department of Medical Oncology, A Beneficência Portuguesa de São Paulo - BP, São Paulo, SP, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758835919851663DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535734PMC
May 2019

Choice of first-line therapy in metastatic melanoma.

Cancer 2019 Mar 29;125(5):666-669. Epub 2019 Jan 29.

Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31774DOI Listing
March 2019

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

N Engl J Med 2019 03 16;380(12):1116-1127. Epub 2019 Feb 16.

From the Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Dnipropetrovsk Medical Academy of Ministry of Health of Ukraine (V.S.) and Dnipropetrovsk Medical Academy (I.B.), Dnipro, Sumy State University, Sumy Regional Oncology Center, Sumy (I.V.), and Ivano-Frankivsk National Medical University, Ivano-Frankivsk (A.K.) - all in Ukraine; the Russian Scientific Center of Roentgen Radiology (R.G.), Central Clinical Hospital with Outpatient Clinic (D.N.), and Hertzen Moscow Cancer Research Institute (B.A.), Moscow; the Christie NHS Foundation Trust, Manchester (R.H.), and Barts Health and the Royal Free NHS Trusts, Barts Cancer Institute, and Queen Mary University of London, London (T.P.) - all in the United Kingdom; Centre Hospitalier Universitaire (CHU) de Québec and Université Laval, Quebec, QC (F.P.), and CHU de Montréal, Montreal (D.S.) - both in Canada; Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (S.J.A.); Centre Antoine Lacassagne, Université Côte d'Azur, Nice (D.B.), and Hôpitaux Universitaires de Lyon, Lyon (S. Tartas) - both in France; Military Institute of Medicine, Warsaw, Poland (C.S.); Rocky Mountain Cancer Center, Colorado Springs, CO (M.M.); Adelaide and Meath Hospital and University College Dublin, Dublin (R.S.M.); the Department of Urology, Eberhard-Karls University Tübingen, Tübingen, Germany (J.B.); Taipei Veterans General Hospital, Taipei, Taiwan (Y.-H.C.); Osaka City University Hospital, Osaka, Japan (S. Tamada); MSD China, Beijing (Q.S.); Merck, Kenilworth, NJ (R.F.P., M.C.); and Georgetown Lombardi Comprehensive Cancer Center, Washington, DC (M.B.A.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1816714DOI Listing
March 2019

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

N Engl J Med 2019 03 16;380(12):1103-1115. Epub 2019 Feb 16.

From Memorial Sloan Kettering Cancer Center (R.J.M.) and Pfizer (S.H.), New York; Private Medical Institution Euromedservice (K.P.) and Nonstate Health Institution Road Clinical Hospital-Russian Railways (A.V.), St. Petersburg, and the Moscow Scientific Research Oncology Institute, Moscow (B.A.) - all in Russia; the Netherlands Cancer Institute, Amsterdam (J.H.); the Cleveland Clinic, Cleveland (B.R.); Institut Gustave Roussy, Villejuif (L.A.), and Centre Léon Bérard, University of Lyon, Lyon (S.N.) - both in France; the University of Texas M.D. Anderson Cancer Center, Houston (M.T.C.); University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow (B.V.), and Royal Marsden NHS Foundation Trust, London (J.L.) - both in the United Kingdom; British Columbia Cancer Agency, Vancouver (C.K.), and Lady Davis Institute and Jewish General Hospital, McGill University, Montreal (W.H.M.) - both in Canada; Osaka University Hospital, Osaka, Japan (M.U.); University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea (J.L.L.); Macquarie University, Sydney (H.G.); Department of Medicine I, Clinical Division of Oncology and Comprehensive Cancer Center, Medical University of Vienna, Vienna (M.S.); Georgetown Lombardi Comprehensive Cancer Center, Washington, DC (M.B.A.); Department of Urology, University of Tübingen, Tübingen, Germany (J.B.); Pfizer, Cambridge (J.W., A.C.), and the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, and Brigham and Women's Hospital, Boston (T.K.C.) - both in Massachusetts; Pfizer (M.M., A.P.) and Pfizer Italia (C.F.), Milan; Pfizer, San Diego, CA (P.B.R.); and Pfizer, Groton, CT (B.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1816047DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6716603PMC
March 2019

Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors.

J Immunother Cancer 2019 Mar 4;7(1):61. Epub 2019 Mar 4.

Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3970 Reservoir Rd NW, New Research Building Suite E 501, Washington, DC, 20057, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0533-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399858PMC
March 2019

Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma.

Cancer Treat Rev 2018 Nov 20;70:127-137. Epub 2018 Jul 20.

The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2018.07.009DOI Listing
November 2018

Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin.

J Immunother 2018 09;41(7):332-335

MedStar Georgetown University/Washington Hospital Center.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CJI.0000000000000239DOI Listing
September 2018

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

N Engl J Med 2018 Aug;379(8):722-730

From the University of Texas M.D. Anderson Cancer Center, Houston (H.A.T.); Moffitt Cancer Center and Research Institute, Tampa, FL (P.A.F., N.I.K.); University of California-San Francisco, San Francisco (A. Algazi), the Angeles Clinic and Research Institute, Los Angeles (O.H.), Stanford University Hospital, Palo Alto (R.P.T.), and the Department of Medical Oncology, City of Hope, Duarte (K.M.) - all in California; Dana-Farber Cancer Institute, Boston (F.S.H., D.A.R.); University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill (S.J.M.); University of Colorado Comprehensive Cancer Center, Aurora (K.L.); University of Michigan, Ann Arbor (C.D.L.); Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (M.A.P.), Roswell Park Cancer Institute, Buffalo (M.S.E., I.P.), and New York University, Lake Success (A.C.P.) - all in New York; Georgetown-Lombardi Comprehensive Cancer Center, Washington DC (M.B.A.); Winship Cancer Institute of Emory University, Atlanta (R.R.K.); University of Pittsburgh Medical Center, Pittsburgh (A.T.); Bristol-Myers Squibb, Princeton, NJ (J.J., A. Avila, S.D.); and Cleveland Clinic-Taussig Cancer Institute, Cleveland (A.T.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1805453DOI Listing
August 2018

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

J Clin Oncol 2018 06 14;36(17):1714-1768. Epub 2018 Feb 14.

Julie R. Brahmer, Johns Hopkins Kimmel Cancer Center; Jennifer S. Mammen, Johns Hopkins University, Baltimore, MD; Christina Lacchetti, American Society of Clinical Oncology, Alexandria; Alexander Spira, Virginia Cancer Specialists and US Oncology Research, Fairfax, VA; Bryan J. Schneider, University of Michigan Health System, Ann Arbor, MI; Michael B. Atkins, Georgetown Lombardi Comprehensive Cancer Center; Cristina A. Reichner, Georgetown University; Laura D. Porter, Colon Cancer Alliance; Washington, DC; Kelly J. Brassil, Aung Naing, Loretta J. Nastoupil, Maria E. Suarez-Almazor, and Yinghong Wang, MD Anderson Cancer Center, Houston, TX; Jeffrey M. Caterino, The Ohio State University Wexner Medical Center, Columbus, OH; Ian Chau, The Royal Marsden Hospital and Institute of Cancer Research, London and Surrey, United Kingdom; Marc S. Ernstoff and Igor Puzanov, Roswell Park Cancer Institute, Buffalo; Bianca D. Santomasso and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center; Jeffrey S. Weber, New York University Langone Medical Center, New York, NY; Pamela Ginex, Oncology Nursing Society, Pittsburgh, PA; Jennifer M. Gardner, Seattle Cancer Care Alliance and University of Washington, Seattle, WA; Sigrun Hallmeyer, Oncology Specialists SC, Park Ridge, IL; Jennifer Holter Chakrabarty, University of Oklahoma, Stephenson Cancer Center, Oklahoma City, OK; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; David F. McDermott, Beth Israel Deaconess Medical Center; Carole Seigel, Massachusetts General Hospital Cancer Center, Boston, MA; John A. Thompson, Seattle Cancer Care Alliance, University of Washington, and the Fred Hutchinson Cancer Research Center, Seattle, WA; and Tanyanika Phillips, CHRISTUS St Frances Cabrini Cancer Center, Alexandria, LA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.6385DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481621PMC
June 2018

Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review.

Oncologist 2018 05 27;23(5):540-555. Epub 2018 Feb 27.

Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C., USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2017-0534DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947457PMC
May 2018

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.

J Clin Oncol 2018 02 17;36(4):391-398. Epub 2017 Oct 17.

Margaret K. Callahan, Michael A. Postow, Neil H. Segal, Alexander Lesokhin, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, NY; Harriet Kluger and Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, and Yale-New Haven Hospital, New Haven, CT; Michael B. Atkins, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; John M. Kirkwood, University of Pittsburgh Medical Center, Pittsburgh, PA; and Suba Krishnan, Rafia Bhore, and Christine Horak, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.72.2850
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.72.2850DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946731PMC
February 2018

Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor-Induced Enteritis.

ACG Case Rep J 2018 28;5:e17. Epub 2018 Feb 28.

Division of Gastroenterology, Medstar Georgetown University Hospital, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14309/crj.2018.17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830540PMC
February 2018

Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.

J Immunother Cancer 2018 01 29;6(1). Epub 2018 Jan 29.

Department of Hematology & Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Ave, Desk CA60, Cleveland, OH, 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-018-0319-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789686PMC
January 2018

Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.

J Clin Oncol 2017 Dec 15;35(34):3815-3822. Epub 2017 Sep 15.

Mario Sznol, Yale Comprehensive Cancer Center, New Haven, CT; Pier Francesco Ferrucci, Istituto Europeo di Oncologia, Milan; Massimo Guidoboni, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; David Hogg, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Michael B. Atkins, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Pascal Wolter, University Hospitals Leuven, Leuven, Belgium; Celeste Lebbé, Université Paris Diderot, Paris; Luc Thomas, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France; John M. Kirkwood, Hillman Cancer Center, Pittsburgh, PA; Jacob Schachter, Sheba Medical Center, Ramat Gan, Israel; Gregory A. Daniels, University of California San Diego, Moores Cancer Center, La Jolla, CA; Jessica Hassel, University Hospital, Heidelberg, Germany; Jonathan Cebon, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria; Winald Gerritsen, University of Queensland, St Lucia; Victoria Atkinson, Gallipoli Medical Research Foundation, Greenslopes; Victoria Atkinson, Princess Alexandra Hospital, Brisbane, Queensland, Australia; Winald Gerritsen, Radboud University Medical Center, Nijmegen, the Netherlands; John McCaffrey, Irish Clinical Oncology Research Group, Dublin; Derek Power, Irish Clinical Oncology Research Group, Cork, Ireland; Dana Walker, Rafia Bhore, and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; and Jedd D. Wolchok, Parker Institute and Ludwig Center at Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.72.1167DOI Listing
December 2017

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

N Engl J Med 2017 11 10;377(19):1824-1835. Epub 2017 Sep 10.

From New York University Perlmutter Cancer Center, New York (J.W.); Papa Giovanni XXIII Cancer Center Hospital, Bergamo (M. Mandala), Medical Oncology, National Cancer Institute, Milan (M.D.V.), Oncology Institute of Veneto Istituti di Ricovero e Cura a Carattere Scientifico, Padua (V.C.-S.), Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena (M. Maio), Ospedale Policlinico San Martino, Genoa (P.Q.), and Istituto Nazionale Tumori Fondazione Pascale, Naples (P.A.A.) - all in Italy; National and Kapodistrian University of Athens, Athens (H.J.G.); Hospital Clinic de Barcelona, Barcelona (A.M.A.), and General University Hospital Gregorio Marañón, Madrid (I.M.-R.) - both in Spain; Texas Oncology-Baylor Cancer Center, Dallas (C.L.C.); Hospices Civils de Lyon, Pierre Bénite (S.D.), Aix-Marseille University, Hospital de la Timone, Marseille (J.-J.G.), Institut Universitaire du Cancer de Toulouse and Centre Hospitalier Universitaire (CHU), Toulouse (N.M.), Université Lille, INSERM Unité 1189, CHU Lille, Lille (L.M.), and Assistance Publique-Hôpitaux de Paris, Dermatology and Centres d'Investigation Clinique, INSERM Unité 976, Hôpital Saint Louis, Université Paris Diderot, Paris (C.L.) - all in France; Oncology Center Sf. Nectarie, Craiova, Romania (M. Schenker); Princess Margaret Cancer Centre, University of Toronto, Toronto (M.O.B.), and Cross Cancer Institute, Edmonton, AB (M. Smylie) - both in Canada; the Department of Oncology, University of Oxford, Oxford (M.R.M.), and Royal Marsden NHS Foundation Trust, London (J.L.) - both in the United Kingdom; Gallipoli Medical Research Foundation and University of Queensland, Queensland, VIC (V.A.), and Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals, Sydney (G.V.L.) - all in Australia; University of Colorado, Denver (R.G.); Winship Cancer Institute, Emory University School of Medicine, Atlanta (R.R.K.); Georgetown-Lombardi Comprehensive Cancer Center, Washington DC (M.B.A.); University of Washington, Seattle (S.B.); Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); Nagoya University Graduate School of Medicine, Nagoya (K.Y.), and the National Cancer Center Hospital, Tokyo (N.Y.) - both in Japan; Seoul National University Hospital, Seoul, South Korea (T.M.K.); and Bristol-Myers Squibb, Princeton, NJ (V.P, J.S., A.Q.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1709030DOI Listing
November 2017

Indoor Tanning Dependence in Young Adult Women.

Cancer Epidemiol Biomarkers Prev 2017 11 19;26(11):1636-1643. Epub 2017 Oct 19.

Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-17-0403DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679408PMC
November 2017

Societal preferences for adjuvant melanoma health states: UK and Australia.

BMC Cancer 2017 Oct 17;17(1):689. Epub 2017 Oct 17.

Outcomes Research Strategies in Health, Washington, DC, 20008, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-017-3673-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5646133PMC
October 2017

Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).

J Clin Oncol 2017 Mar 30;35(8):885-892. Epub 2017 Jan 30.

Sanjiv S. Agarwala, Saint Luke's University Hospital, Easton; Uma N. Rao, Ahmad A. Tarhini, Terry L. Evans, and John M. Kirkwood, University of Pittsburgh Medical Center, Pittsburgh, PA; Sandra J. Lee, and Waiki Yip, Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA; Gary I. Cohen, Greater Baltimore Medical Center, Baltimore, MD; Douglas S. Reintgen, Lakeland Regional Cancer Center, Lakeland; Vernon K. Sondak, H. Lee Moffitt Cancer Center, Tampa, FL; Joanna M. Brell, MetroHealth Medical Center, Cleveland; William E. Carson, The Ohio State University Comprehensive Cancer Center, Columbus, OH; Mark R. Albertini, University of Wisconsin Hospital, Madison, WI; Michael B. Atkins, Georgetown Medical Center, Washington, DC; Shaker R. Dakhil, Cancer Center of Kansas, Wichita, KS; Robert M. Conry, University of Alabama at Birmingham, Birmingham, AL; Jeffrey A. Sosman, Vanderbilt University, Nashville; Alberto S. Pappo, Saint Jude Children's Research Hospital Oncology, Memphis, TN; Lawrence E. Flaherty, Wayne State University/Karmanos Cancer Institute, Detroit, MI; Michael G. Smylie, Cross Cancer Institute, Edmonton, Canada; and Richard F. Kefford, Sydney West Area Health Service, Westmead, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.2951DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455684PMC
March 2017

Surgical Management and Adjuvant Therapy for High-Risk and Metastatic Melanoma.

Am Soc Clin Oncol Educ Book 2016 ;35:e505-14

From the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; St. Luke's University Hospital, Temple University, Allentown, PA; University of Manchester, The Christie NHS Foundation Trust, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_159087DOI Listing
January 2017

Support for indoor tanning policies among young adult women who indoor tan.

Transl Behav Med 2016 12;6(4):613-621

Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13142-016-0432-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5110500PMC
December 2016

Predictive biomarkers for checkpoint inhibitor-based immunotherapy.

Lancet Oncol 2016 Dec;17(12):e542-e551

Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington DC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)30406-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702534PMC
December 2016

Correlates of Sun Safety Practices in a Racially and Ethnically Diverse Sample of Adolescents: Implications for Skin Cancer Prevention Interventions.

Pediatr Dermatol 2015 Nov-Dec;32(6):e288-90. Epub 2015 Aug 13.

Department of Oncology, Georgetown University Medical Center, Lombardi Comprehensive Cancer Center, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pde.12642DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4654685PMC
September 2016

Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC).

Expert Opin Emerg Drugs 2016 Sep;21(3):243-54

b Division of Hematology/Oncology , Medstar Georgetown University Hospital , Washington , DC , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2016.1226798DOI Listing
September 2016

Discordance Between Cobas BRAF V600 Testing and VE1 Immunohistochemistry in a Melanoma Patient With Bone Marrow Metastases.

Am J Dermatopathol 2016 Sep;38(9):687-9

*Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC; †Memorial Sloan Kettering Cancer Center, New York, NY; and ‡George Washington University, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0000000000000660DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510737PMC
September 2016

Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma.

Clin Genitourin Cancer 2016 08 23;14(4):304-313.e6. Epub 2016 Feb 23.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2016.02.007DOI Listing
August 2016

Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives.

J Natl Cancer Inst 2016 Jun 2;108(6):djv414. Epub 2016 Feb 2.

Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC (MBA); Royal Marsden Hospital, London, UK (JL).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djv414DOI Listing
June 2016

Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG).

Int J Radiat Oncol Biol Phys 2016 06;95(2):632-46

Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

View Article

Download full-text PDF

Source
http://ocpe.mcw.edu/sites/ocpe.mcw.edu/files/users/561/Avoid
Web Search
http://dx.doi.org/10.1016/j.ijrobp.2016.01.038DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5102246PMC
June 2016

What is optimal first-line treatment of unresectable or advanced BRAF-mutant melanoma?

Authors:
Michael B Atkins

Clin Adv Hematol Oncol 2016 Jun;14(6):417-9

Georgetown Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC.

View Article

Download full-text PDF

Source
June 2016

Advances in immunotherapy for melanoma.

BMC Med 2016 Feb 6;14:20. Epub 2016 Feb 6.

Georgetown Lombardi Comprehensive Cancer Center 3970 Reservoir Road, NW Research Building, Room E501, 20007, Washington DC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12916-016-0571-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744430PMC
February 2016

Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma.

Cancer 2016 Jan 6;122(1):124-30. Epub 2015 Oct 6.

Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29728DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602387PMC
January 2016

Treatment of Melanoma CNS Metastases.

Cancer Treat Res 2016 ;167:263-79

Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C., USA.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/978-3-319-22539
Web Search
http://link.springer.com/10.1007/978-3-319-22539-5_11
Publisher Site
http://dx.doi.org/10.1007/978-3-319-22539-5_11DOI Listing
January 2016

Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697).

J Clin Oncol 2015 Dec 8;33(34):4066-76. Epub 2015 Sep 8.

David H. Lawson, Winship Cancer Institute of Emory University, Atlanta, GA; Sandra Lee and Fengmin Zhao, Dana-Farber Cancer Institute; Michael B. Atkins, Beth Israel Deaconess Medical Center, Boston, MA; Ahmad A. Tarhini, Theresa L. Whiteside, Lisa H. Butterfield, and John M. Kirkwood, University of Pittsburgh Medical Center, Pittsburgh, PA; Kim A. Margolin, Seattle Cancer Care Alliance, Seattle, WA; Marc S. Ernstoff, Dartmouth-Hitchcock Medical Center, Lebanon, NH; and Gary I. Cohen, Greater Baltimore Medical Center, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.0500DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669592PMC
December 2015

New agents and new targets for renal cell carcinoma.

Am Soc Clin Oncol Educ Book 2014 :e222-7

From the Department of Oncology, Georgetown-Lombardi Comprehensive Cancer Center and Division of Hematology/Oncology, Medstar Georgetown University Hospital, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2014.34.e222DOI Listing
November 2015

Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma.

Cancer Immunol Res 2015 Oct 26;3(10):1158-64. Epub 2015 May 26.

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Kidney Cancer Program, Dana-Farber Harvard Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0043DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4596765PMC
October 2015

Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma.

Cancer 2015 Oct 8;121(19):3435-43. Epub 2015 Jun 8.

Kidney Cancer Center, The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29503DOI Listing
October 2015

Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study.

J Clin Oncol 2015 Oct 24;33(30):3431-8. Epub 2015 Aug 24.

Michael B. Atkins, Georgetown University, Washington, DC; Gwenaelle Gravis, Institut Paoli Calmettes, Marseille; Alain Ravaud, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint André, Bordeaux, France; Kazimierz Drosik, Regional Cancer Center, Opole; Tomasz Demkow, Maria Skłodowska-Curie Memorial Cancer Center, Warsaw; Piotr Tomczak, University of Medical Sciences, Poznan, Poland; Shirley S. Wong, Western Hospital, Footscray, Victoria, Australia; M. Dror Michaelson, Massachusetts General Hospital; Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA; and Benjamin Wu, Lynn Navale, and Douglas Warner, Amgen, Thousand Oaks, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.6012DOI Listing
October 2015

Cancer Immunotherapy: Past Progress and Future Directions.

Semin Oncol 2015 Aug 3;42(4):518-22. Epub 2015 Jun 3.

Department of Internal Medicine and Melanoma Unit, Yale Cancer Center, New Haven, CT. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2015.05.001DOI Listing
August 2015

BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).

J Clin Oncol 2015 Jul 15;33(21):2384-91. Epub 2015 Jun 15.

Keith T. Flaherty, University of Pennsylvania, Philadelphia, PA; Judith B. Manola, Dana-Farber Cancer Institute; David F. McDermott and Michael B. Atkins, Beth Israel Deaconess Medical Center, Boston, MA; Michael Pins, Advocate Lutheran General Hospital, Park Ridge, IL; Janice J. Dutcher, Montefiore Medical Center, Bronx, NY; Daniel J. George, Duke University Medical Center, Durham, NC; Kim A. Margolin, Seattle Cancer Care Alliance, University of Washington, Seattle, WA; and Robert S. DiPaola, Cancer Institute of New Jersey at Hamilton, New Brunswick, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.60.9727DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500832PMC
July 2015

What's new in melanoma? Combination!

J Transl Med 2015 Jul 4;13:213. Epub 2015 Jul 4.

Oncology and Medicine, Georgetown-Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, 3970 Reservoir Rd NW, Washington, DC, 20057, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12967-015-0582-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491255PMC
July 2015

Immunotherapy or molecularly targeted therapy: what is the best initial treatment for stage IV BRAF-mutant melanoma?

Clin Adv Hematol Oncol 2015 Jul;13(7):451-8

Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC.

View Article

Download full-text PDF

Source
http://www.hematologyandoncology.net/files/2015/07/GibneyAtk
Web Search
July 2015

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.

J Clin Oncol 2015 Jun 30;33(18):2013-20. Epub 2015 Mar 30.

David F. McDermott, Beth Israel Deaconess Medical Center; Toni K. Choueiri, Dana-Farber Cancer Institute/Brigham and Women's Hospital; Igor Puzanov and F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Charles G. Drake, Julie R. Brahmer, Hans J. Hammers, Suzanne L. Topalian, and Drew M. Pardoll, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; John D. Powderly, Carolina BioOncology Institute, Huntersville, NC; David C. Smith, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Richard D. Carvajal, Memorial Sloan-Kettering Cancer Center, New York, NY; Jon M. Wigginton, Georgia D. Kollia, Ashok Gupta, Dan McDonald, and Vindira Sankar, Bristol-Myers Squibb, Princeton, NJ; Jeffrey A. Sosman, Vanderbilt-Ingram Cancer Center, Nashville, TN; and Michael B. Atkins, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.58.1041DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517051PMC
June 2015

Toxicities of Immunotherapy for the Practitioner.

J Clin Oncol 2015 Jun 27;33(18):2092-9. Epub 2015 Apr 27.

Jeffrey S. Weber, Moffitt Cancer Center, Tampa, FL; James C. Yang, National Cancer Institute, Bethesda, MD; Michael B. Atkins, Lombardi Cancer Center, Georgetown University, Washington, DC; and Mary L. Disis, The Fred Hutchinson Cancer Center, University of Washington, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.0379DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881375PMC
June 2015

Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic Melanoma.

J Clin Oncol 2015 Jun 11;33(17):1873-7. Epub 2015 May 11.

Georgetown-Lombardi Comprehensive Cancer Center; and Medstar-Georgetown University Hospital, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.1807DOI Listing
June 2015

Bowel perforation associated with robust response to BRAF/MEK inhibitor therapy for -mutant melanoma: a case report.

Melanoma Manag 2015 May 18;2(2):115-120. Epub 2015 May 18.

Department of Oncology, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC 20057, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt.15.10DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094601PMC
May 2015

Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer.

Clin Cancer Res 2015 Apr 14;21(8):1925-1934. Epub 2015 Jan 14.

Division of Hematology-Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, Massachusetts, 02215, United States of America.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4419371PMC
April 2015

Ipilimumab associated colitis: an IpiColitis case series at MedStar Georgetown University Hospital.

World J Gastroenterol 2015 Apr;21(14):4373-8

Pawan Rastogi, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC 20007, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3748/wjg.v21.i14.4373DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4394100PMC
April 2015

Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.

J Clin Oncol 2014 Nov 20;32(33):3771-8. Epub 2014 Oct 20.

Lawrence E. Flaherty, Wayne State University, Detroit; Bruce G. Redman, University of Michigan, Ann Arbor, MI; Megan Othus, James Moon, Southwest Oncology Group Statistical Center; John A. Thompson, Seattle Cancer Care Alliance, Seattle, WA; Michael B. Atkins, Georgetown University Hospital, Washington DC; Ralph J. Tuthill, Cleveland Clinic Foundation, Cleveland, OH; John T. Vetto, Oregon Health & Science University/Knight Cancer Institute, Portland, OR; Frank G. Haluska, Tufts-New England Medical Center, Boston, MA; Alberto S. Pappo, Texas Children's Cancer Center, Houston, TX; Jeffrey A. Sosman, Vanderbilt University School of Medicine Nashville, TN; Antoni Ribas, University of California Los Angeles, Los Angeles, CA; John M. Kirkwood, University of Pittsburgh Medical Center, Pittsburgh, PA; Vernon K. Sondak, H. Lee Moffitt Cancer Center, Tampa, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.1590DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226807PMC
November 2014

Prognostic and predictive markers for the new immunotherapies.

Oncology (Williston Park) 2014 Nov;28 Suppl 3:39-48

View Article

Download full-text PDF

Source
November 2014

Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report.

Melanoma Res 2014 Oct;24(5):509-11

aDivision of Hematology/Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center bMelanoma Disease Group, Medstar-Georgetown Cancer Network, Washington, District of Columbia cDivision of Surgical Oncology, Medstar-Georgetown University Hospital, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000102DOI Listing
October 2014

A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study.

J Immunother 2013 Nov-Dec;36(9):490-5

*Dartmouth Hitchcock Medical Center, Lebanon, NH †Dana-Farber Cancer Institute, Harvard School of Public Health ∥Beth Israel Deaconess Medical Center ‡‡Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA ‡Vanderbilt University Medical Center, Nashville, TN §Loyola University Medical Center, Maywood, IL ¶Georgetown Lombardi Comprehensive Cancer Center, Washington, DC #St. Luke's Roosevelt Hospital Center, New York, NY **Earle A. Chiles Research Institute ††Providence Cancer Center, Portland, OR §§Department of Oncology, Wayne State University, Karmanos Cancer Institute, Detroit, MI ∥∥Division of Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, WA.

View Article

Download full-text PDF

Source
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/CJI.0000000000000003DOI Listing
June 2014

Emerging clinical issues in melanoma in the molecularly targeted era.

Methods Mol Biol 2014 ;1102:11-26

Center for Melanoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-62703-727-3_2DOI Listing
June 2014

Molecular pathways: can activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors?

Clin Cancer Res 2014 Jun 8;20(11):2838-45. Epub 2014 Apr 8.

Authors' Affiliations: Division of Hematology-Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts and Departments of Oncology and Medicine, Georgetown-Lombardi Comprehensive Cancer Center, Washington, District of Columbia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-2788DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112731PMC
June 2014

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

J Clin Oncol 2014 Apr 3;32(10):1020-30. Epub 2014 Mar 3.

Suzanne L. Topalian, William H. Sharfman, Julie R. Brahmer, Evan J. Lipson, Janis M. Taube, and Drew M. Pardoll, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Mario Sznol and Harriet M. Kluger, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; David F. McDermott, Beth Israel Deaconess Medical Center; Donald P. Lawrence, Massachusetts General Hospital Cancer Center; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Richard D. Carvajal, Memorial Sloan-Kettering Cancer Center, New York, NY; Michael B. Atkins, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; John D. Powderly, Carolina BioOncology Institute, Huntersville, NC; Philip D. Leming, The Christ Hospital Cancer Center, Cincinnati, OH; Igor Puzanov and Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; David C. Smith, University of Michigan, Ann Arbor, MI; and Jon M. Wigginton, Georgia D. Kollia, and Ashok Gupta, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.0105DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811023PMC
April 2014

The role of angiopoietins as potential therapeutic targets in renal cell carcinoma.

Transl Oncol 2014 Apr 4;7(2):188-95. Epub 2014 Mar 4.

Division of Hematology-Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tranon.2014.02.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4101387PMC
April 2014

Tumor necrosis on magnetic resonance imaging correlates with aggressive histology and disease progression in clear cell renal cell carcinoma.

Clin Genitourin Cancer 2014 Feb 19;12(1):55-62. Epub 2013 Oct 19.

Department of Radiology, St. James Hospital and Trinity College, Dublin, Ireland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2013.07.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364293PMC
February 2014

PD-1 as a potential target in cancer therapy.

Cancer Med 2013 Oct 21;2(5):662-73. Epub 2013 Jul 21.

Biologic Therapy Program, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892798PMC
October 2013